Skip to main content
Equibles
ARCT logo

ARCT · Arcturus Therapeutics Holdings Inc. · Metrics

Track ARCT — free

Use ARCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.84 -0.89 (-8.29%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$285.23M
Shares
28.42M
Volume · Oct 23 475K Avg daily vol (3M) 939.9K

ARCT metrics

83 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.84
Market cap
$285.23M

Price action

20 metrics
Price change (1W)
-4.8%
Price change (30D)
-30.3%
Price change (3M)
+77.9%
Price change (6M)
+14.6%
Price change (YTD)
+60.5%
Price change (1Y)
-18.0%
Trailing year
Price change (5Y)
-77.9%
52-week high
$16.93
52-week low
$5.53
Change from 52-week high
-41.9%
Change from 52-week low
+77.9%
Annualized volatility
77.1%
Annualized volatility (3M)
112.6%
Beta
1.8
RSI (14D)
35.0
Price vs SMA 50
-26.6%
Price vs SMA 200
+10.5%
Avg volume (3M)
939,900
Relative volume
0.5
Average dollar volume
$11.91M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
28.42M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
3.2×
reciprocal yield 31.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
9.7×
reciprocal yield 10.3%
P / book
1.7
reciprocal yield 60.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-32.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.4×
reciprocal yield 73.3%
EV / revenue historical average (5Y)
11.8×
reciprocal yield 8.5%
EV / EBIT historical average (3Y)
12.6×
reciprocal yield 7.9%
EV / EBIT historical average (5Y)
12.6×
reciprocal yield 7.9%
EV / EBITDA historical average (3Y)
11.7×
reciprocal yield 8.6%
EV / EBITDA historical average (5Y)
11.7×
reciprocal yield 8.6%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-348.3%
Trailing 12 months
Net margin
-317.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$102.29M
Net income (TTM)
−$93.28M
Trailing 12 months
Diluted EPS (TTM)
$-3.33
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.06
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.64
EBITDA per diluted share (TTM)
$-3.54
Net income per diluted share (TTM)
$-3.31
Operating cash flow per diluted share (TTM)
$-2.59
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$3.10
Stock compensation per diluted share (TTM)
$0.75
Book value per share
$7.53

Growth

11 metrics
Revenue growth YoY
-89.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$29.37M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.8%
Year over year · more shares
Revenue CAGR (3Y)
-26.4%
Revenue CAGR (5Y)
+53.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-54.3%
Return on assets
-41.6%
Debt / equity
0.0
Current ratio
5.9
EBITDA (TTM)
−$99.61M
Free cash flow (TTM)
—
Quick ratio
5.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$191.48M
Latest balance sheet
Cash & equivalents
$191.48M
Total assets
$224.31M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$72.73M
Capital expenditures (TTM)
$93,000
R&D (TTM)
$86.78M
SG&A (TTM)
—
Stock compensation (TTM)
$21.10M
R&D / revenue
295.5%
Stock compensation / revenue
71.9%

Ownership (13F)

9 metrics
13F filers
136
13F filer change QoQ
+11
Institutional ownership
88.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
27.1%
Private-fund adviser ownership
24.8%
Active holders' share change QoQ
+5.5%
Holder tenure
17.2
Price vs estimated holder cost
-71.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.5%

Short interest

3 metrics
Short interest
18.9%
Latest settlement · 5.9 days to cover
Days to cover
5.9d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1768224 CUSIP 03969T109 13F (30d) 19 filings 19 filers Visit website Investor relations